A Study of LY2541546 in Healthy Postmenopausal Women
| Status: | Completed |
|---|---|
| Conditions: | Healthy Studies |
| Therapuetic Areas: | Other |
| Healthy: | No |
| Age Range: | 45 - 70 |
| Updated: | 1/25/2019 |
| Start Date: | June 2008 |
| End Date: | June 2010 |
A Single-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY2541546 in Healthy Postmenopausal Women
The purpose of this study is to determine if a single dose of LY2541546 has any side effects
on the body and to determine how long and how much LY2541546 stays in the bloodstream of the
body.
on the body and to determine how long and how much LY2541546 stays in the bloodstream of the
body.
Inclusion Criteria:
- Healthy postmenopausal females, as determined by medical history and physical
examination
- Body mass index (BMI) at screening between 19.0 and 32.0 kilograms per square meter
(kg/m^2), inclusive
- Acceptable Clinical laboratory test results, blood pressure and heart rate
- Have given written informed consent
- Additional Inclusion Criterion for Participants in Open Label Groups: Are currently
taking or recently discontinued (not more than 3 months prior to study randomization)
alendronate and have taken alendronate for at least 12 of the last 18 months
Exclusion Criteria:
- Within 30 days of the initial dose of study drug, have received treatment with a drug
that has not received regulatory approval for any indication
- Known allergies to LY2541546, its constituents, or related compounds
- Persons who have previously participated in this study
- History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal,
endocrine, hematological, or neurological disorders
- History of or high risk for adverse outcome from bleeding, for example, transient
ischemic attacks, cerebrovascular attacks, and ulcer disease
- Paget's disease, parathyroid disease, or thyroid disease
- Fracture of a long bone within 12 weeks of screening
- Regular use of known drugs of abuse and/or positive findings on urinary drug screening
- Evidence of human immunodeficiency virus (HIV), hepatitis C, hepatitis B and/or
positive for anti-HIV antibodies, hepatitis C antibody, or hepatitis B surface antigen
- Current use of therapies for osteoporosis or use of hormone replacement therapy (HRT)
within the previous 12 months
- Blood donation within the last month
- Participants who have an average weekly alcohol intake that exceeds 14 units per week
- Cigarette consumption of more than 10 cigarettes per day, or are unable or unwilling
to refrain from nicotine during Clinical Research Unit (CRU) confinement
Additional Exclusion Criterion for Participants in Double Blind Groups Only
- Have received bisphosphonates during the previous 24 months.
Additional Exclusion Criterion for Participants in Open Label Groups
- Have received intravenous bisphosphonates within the previous 18 months
We found this trial at
2
sites
Click here to add this to my saved trials
Click here to add this to my saved trials